Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 7/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | VDR | P11473 | 1/20 | 0.52 |
| ▸ | CDC25A | P30304 | 3/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 3/20 | 0.50 |
| ▸ | FNTB | P49356 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441278 | 0.90 | NPC1L1 (0.73) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL25336778 | 0.83 | NPC1L1 (0.53) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL25336776 | 0.83 | NPC1L1 (0.53) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL11786452 | 0.80 | NPC1L1 (0.58) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL11786454 | 0.80 | NPC1L1 (0.58) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL15301588 | 0.80 | NPC1L1 (0.59) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL23628433 | 0.80 | NPC1L1 (0.59) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL29819604 | 0.80 | NPC1L1 (0.62) | NPC1L1USP2MEN1LMNATP53 | |
| SCHEMBL8902782 | 0.79 | CDC25A (0.75) | USP2VDRCDC25APOLA1 | |
| SCHEMBL17124650 | 0.79 | CDC25A (0.75) | USP2VDRCDC25APOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260098152-A1 | RESIN COMPOSITION AND MOLDED ARTICLE OF SAME | TEIJIN LIMITED (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20260007065-A1 | ELECTROLUMINESCENT DEVICE COMPRISING A METAL ORGANIC COORDINATION COMPOUND WITH ELECTRONIC SPIN AS HOST MATERIAL | BEEOLED GMBH (DE) | 2026-01-01 | — | — | US | disclosed |
| EP-4658039-A1 | ELECTROLUMINESCENT DEVICE COMPRISING A METAL ORGANIC COORDINATION COMPOUND WITH ELECTRONIC SPIN AS HOST MATERIAL | beeOLED GmbH (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-12421336-B2 | Orthodontic articles comprising cured free-radically polymerizable composition with improved strength in aqueous environment | Solventum Intellectual Properties (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4596627-A1 | RESIN COMPOSITION AND MOLDED ARTICLE OF SAME | Teijin Limited (JP) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025134706-A1 | METHOD FOR MANUFACTURING OPTICAL COMPONENT | 三菱瓦斯化学株式会社 | 2025-06-26 | — | — | WO | disclosed |
| US-12326587-B2 | Optical element | CANON KABUSHIKI KAISHA (JP) | 2025-06-10 | — | — | US | disclosed |
| CN-119948103-A | Resin composition and molded article thereof | 帝人株式会社 | 2025-05-06 | — | — | CN | disclosed |
| US-20250059239-A1 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | SANA BIOTECHNOLOGY, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-11584817-B2 | Orthodontic articles comprising cured free-radically polymerizable composition with improved strength in aqueous environment | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220381965-A1 | OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2022-12-01 | — | — | US | disclosed |
| CN-113698114-B | Blocky quicklime doped pulverized lime mortar for historic building restoration and preparation method thereof | 故宫博物院 | 2022-09-16 | — | — | CN | disclosed |
| US-20220290181-A1 | CODON OPTIMIZED RPGRORF15 GENES AND USES THEREOF | 4D MOLECULAR THERAPEUTICS INC (US) | 2022-09-15 | — | — | US | disclosed |
| CN-114681442-A | Active ingredient of antiallergic fermented product and application thereof | 大江生医股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-11345930-B2 | Codon optimized RPGRORF15 genes and uses thereof | 4D MOLECULAR THERAPEUTICS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022098797-A1 | THERAPEUTIC TARGETING OF MESOTHELIN IN ACUTE MYELOID LEUKEMIA WITH CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022091848-A1 | SURFACE PROTECTION FILM, LIGHTING COVER, AND METHOD FOR MANUFACTURING SURFACE PROTECTION FILM | 東海光学株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022051232-A1 | CODON OPTIMIZED RPGRORF 15 GENES AND USES THEREOF | 4D MOLECULAR THERAPEUTICS INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220064673-A1 | CODON OPTIMIZED RPGRORF15 GENES AND USES THEREOF | 4D MOLECULAR THERAPEUTICS INC. (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007065-A1 | ELECTROLUMINESCENT DEVICE COMPRISING A METAL ORGANIC COORDINATION COMPOUND WITH ELECTRONIC SPIN AS HOST MATERIAL | EML4, EMC2, EMC3 | NPC1L1 1780/4885USP2 4604/4885MEN1 262/4885 |
| US-20260098152-A1 | RESIN COMPOSITION AND MOLDED ARTICLE OF SAME | CYC1, MT-CO2, SCO2 | NPC1L1 4573/4885USP2 3253/4885MEN1 4202/4885 |
| US-12421336-B2 | Orthodontic articles comprising cured free-radically polymerizable composition with improved strength in aqueous environment | ELL, PCNA, PAM | NPC1L1 4755/4885USP2 620/4885MEN1 3567/4885 |
| US-11584817-B2 | Orthodontic articles comprising cured free-radically polymerizable composition with improved strength in aqueous environment | ELL, PCNA, PAM | NPC1L1 4755/4885USP2 620/4885MEN1 3567/4885 |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MOK, TTK, MAPK4 | NPC1L1 4793/4885USP2 1364/4885MEN1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.